Estimated yearly progression rates v observed changes in placebo treatment groups
| Variable | US 3017 | MN 3017 | ATTRACT9 | European IL1Ra12 |
|---|---|---|---|---|
| *Estimated annual progression rates are based on six months’ treatment. | ||||
| Mean disease duration (years) | 6.9 | 5.7 | 10.9 | 3.7 |
| Baseline total composite score | 25.4 | 46.2 | 81.9 | 27.4 |
| Estimated 6 or 12 month progression rates at baseline | 3.7 | 8.2* | 7.7 | 7.4* |
| Observed yearly progression rates in placebo groups over 6 or 12 months | 2.2 | 11.8* | 7.0 | 7.0* |